Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer

Anaerobe

Volumn 47, Issue , 2017, Pages 47-50

  Wilson, Heather L ^a   Ong, Chong Wei ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Anaerobe; Bifidobacterium; Cancer; Cirrhosis; Vertebrodiscitis

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; FLUCLOXACILLIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; RNA 16S; ANTIINFECTIVE AGENT;

AGED; ARTICLE; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM LONGUM; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISKITIS; DRUG RESPONSE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; INFECTION RISK; LIVER CIRRHOSIS; MALE; MEDICAL HISTORY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHLEGMON; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; TREATMENT DURATION; VERTEBRODISKITIS; BIFIDOBACTERIALES INFECTION; COMPLICATION; FIBROSIS; ISOLATION AND PURIFICATION; LUMBOSACRAL REGION; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIALES INFECTIONS; BIFIDOBACTERIUM LONGUM; DISCITIS; FIBROSIS; HUMANS; LUMBOSACRAL REGION; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85018334558     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2017.04.004     Document Type: Article

References (21)

1. [1] Jorgensen, J.H., Pfaller, J.A., Carroll, K.C., et al. (eds.) Manual of Clinical Microbiology, eleventh ed., 2015, ASM Press, Washington.
2. [2] Matsuki, T., Watanabe, K., Tanaka, R., et al. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl. Environ. Microbiol. 65 (1999), 4506–4512.
3. [3] Turroni, F., Ribbera, A., Foroni, E., et al. Human gut microbiota and bifidobacteria: from composition to functionality. Antonie Leeuwenhoek 94 (2008), 35–50.
4. [4] Guarino, A., Guandalini, S., Vecchio, A.L., Probiotics for the prevention and treatment of diarrhea. J. Clin. Gastroenterol. 49 (2015), S37–S45.
5. [5] Sood, A., Midha, V., Makharia, G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 7 (2009), 1202–1209.
6. [6] Mahlen, S.D., Clarridge, J.E. III, Site and clinical significance of Alloscardovia omnicolens and Bifidobacterium species isolated in the clinical laboratory. J. Clin. Microbiol. 47 (2009), 3289–3293.
7. [7] Bertelli, C., Pillonel, T., Torregrossa, A., et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin. Infect. Dis. 60 (2015), 924–927.
8. [8] Zbinden, A., Zbinden, R., Berger, C., et al. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107 (2015), 56–59.
9. [9] Tena, D., Losa, C., Medina, M.J., et al. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 27 (2014), 27–30.
10. [10] Ha, G.Y., Yang, C.H., Kim, H., et al. Case of sepsis caused by Bifidobacterium longum. J. Clin. Microbiol. 37 (1999), 1227–1228.
11. th ed., 2017, Clinical and Laboratory Standards Institute, Wayne, PA.
12. [12] The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, 2017. http://www.eucast.org.
13. [13] Bourne, K.A., Beebe, J.L., Lue, Y.A., et al. Bacteremia due to Bifidobacterium, Eubacterium or Lactobacillus; twenty-one cases and review of the literature. Yale J. Biol. Med. 51 (1978), 505–512.
14. [14] Angelakis, E., Million, M., Henry, M., et al. Rapid and accurate bacterial identification in probiotics and yoghurts by MALDI-TOF mass spectrometry. J. Food Sci. 76 (2011), M568–M572.
15. [15] Veloo, A.C.M., Elgersma, P.E., Friedrich, A.W., et al. The influence of incubation time, sample preparation and exposure to oxygen on the quality of the MALDI-TOF MS spectrum of anaerobic bacteria. Clin. Microbiol. Infect. 20 (2014), 1091–1097.
16. [16] Moubareck, C., Gavini, F., Vaugien, L., et al. Antimicrobial susceptibility of bifidobacteria. J. Antimicrob. Chemother. 55 (2005), 38–44.
17. [17] Delgado, S., Florez, A.B., Mayo, B., Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr. Microbiol. 50 (2005), 202–207.
18. [18] Cryan, B., Azadian, B.S., Dunwoody, G.W., et al. Epidural abscess due to Streptococcus milleri and Bifidobacterium species. J. Infect. 23 (1991), 214–215.
19. [19] Brook, I., Frazier, E.H., Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin. Infect. Dis. 16 (1993), 476–480.
20. [20] Bjarnason, I., Ward, K., Peters, T.J., The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 323 (1984), 179–182.
21. [21] Bartoletti, M., Giannella, M., Lewis, R.E., et al. Bloodstream infections in patients with liver cirrhosis. Virulence 7 (2016), 309–319.